Optinol 0.21% Eye Drops 10 ml

The instruction for medical use of a product of medical purpose for the consumer the Name of a product of medical purpose Optinol Kapli eye 0.21%, 0.4% 10 ml Structure and the description of a product Rolled into one contains: Sodium hyalrunate – 0.21% (for the Optinol form of 0.21%), 0.4% (for the Optinol form of 0.4%) Sodium chloride (sea salt) – 0.83% of Sodium dihydrophosphate a dihydrate – 0.07% of Dinatrium hydrophosphate anhydrous – 0.11% the Water purified - up to 100% does not contain preservatives. Optinol is the viscous drops containing sodium hyaluronate which provide moistening and protection of an eye for a long time. Name and (or) trademark of the JSC YaDRAN manufacturing organization Galenski of the Drop Scope Laboratories Optinol: - eliminate the symptomatology of a dry eye which is characterized by discomfort, dryness, burning, feeling of a foreign body - eliminate the irritation of eyes caused by the conditioner, blinking it is long the working TV or the monitor of the computer, - eliminates with dust, smoke, ultraviolet rays, dry heat, wind, etc. a photophobia - are used for prevention and/or elimination of symptoms of a syndrome of a dry eye when using contact lenses, ophthalmologic drugs of anti-inflammatory action, medicines of systemic action (the antidepressants, drugs reducing arterial blood pressure, the combined oral contraceptives) - used for prevention and/or elimination of symptoms of a syndrome of a dry eye at dishormonal (pregnancy, a lactation, a menopause and so forth) and metabolic (a pseudorheumatism, diabetes, diseases of a thyroid gland and so forth) disturbances - are used for prevention and/or elimination of symptoms of a syndrome of a dry eye at people of old age - are used after surgeries (after consultation with the doctor) Kapli Optinol 0.21% are intended for elimination of symptoms of a syndrome of a dry eye of easy degree. Kapli Optinol 0.4% are intended for elimination of symptoms of a syndrome of a dry eye of average and heavy degrees. The action mechanism Sodium hyaluronate is a part of watery moisture and a vitreous of an eye. Distinctive physical characteristic of sodium hyaluronate — high viscosity and elasticity, ability to hold water. Kapli Optinol, applied for the purpose of elimination of symptoms of a syndrome of a dry eye, form the uniform, remaining for a long time, prerogovichny plaintive film which is not washed away when blinking on a cornea surface and does not cause decrease in visual acuity. A route of administration On 1–2 drops in an eye (as required). Kapli can use unlimited number of times. Kapli do not contain preservatives and by that do not make harmful effects approximately. The bottle with a dropper contains the filter which provides protection of liquid against pollution even abroach. Kapli Optinol 0.21% can be used when carrying contact lenses, without removing a lens. When using drops Optinol 0.4% are recommended to remove contact lenses for 15 minutes during instillation of drops. To Store storage conditions at a temperature not above 30ºС. To store out of children's reach! Expiration date 2 years. After opening of a bottle to use within 180 days. Not to apply after an expiration date. Manufacturing organization: Name, country and also legal address of the JSC Yadran manufacturing organization Galenski of Laboratories 51000, Svilno 20, Rijeka, Croatia. The name, the country and also a legal address of representation in Republic of Kazakhstan Almaty, Luganskogo St. 54, a cat.9, ph. +7 272 62-14-71, +7 272 62-14-48, www.jadran.ru the Name and the address of the organization accepting in the territory of the Republic of Kazakhstan a claim (offer) on products of medical purpose from consumers: Representative office of JSC Yadran Galenski of Laboratories in Republic of Kazakhstan, Almaty, Zhamakayev St. 126, a cat.9, ph. +7 272 718044, www.jadran.ru the Name (designation) of the normative document according to which the product of medical purpose is made: European Pharmacopoeia Additional information: Side effect (influence, individual intolerance) is not revealed Contraindications for use Precautionary measures (safety) Pregnancy and a lactation are not revealed Pregnancy and feeding by a breast is not a contraindication to drug use.